SpyGlass Pharma Reports Positive Results from Clinical Trials of BIM-IOL System for Glaucoma and Ocular Hypertension

SpyGlass Pharma Reports Positive Results from Clinical Trials of BIM-IOL System for Glaucoma and Ocular Hypertension

By, Admin 13 November 2025

  • 36-month FIH data show sustained IOP reduction and drop-free outcomes
  • Phase I/II trial interim results confirm strong efficacy and safety across larger population
  • Phase III planning underway following FDA engagement

Breakthrough in Long-Acting Glaucoma Therapy

SpyGlass Pharma, a late-stage biopharmaceutical company developing long-acting drug delivery therapies for chronic eye diseases, today announced positive results from two clinical trials evaluating its lead product candidate, the Bimatoprost Drug Pad-Intraocular Lens (BIM-IOL) System, for the treatment of elevated intraocular pressure (IOP) in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).

The data, presented by Malik Kahook, M.D., co-founder and president of SpyGlass Pharma, at the Interventional Glaucoma Consortium (IGC) in Salt Lake City, Utah, included 36-month follow-up data from the first-in-human (FIH) trial and three-month interim results from the ongoing Phase I/II trial.

“The BIM-IOL System delivers sustained IOP reduction, drop-free outcomes, and strong visual performance over three years,” said Dr. Kahook. “Our Phase I/II trial shows similar outcomes in a broader patient population, reinforcing its potential to eliminate the adherence burden associated with daily eye drops.”

FIH Results at 36 Months

  • 37% reduction in mean IOP across all dose groups (from 25.1 ± 2.5 mmHg at baseline to 15.9 ± 2.7 mmHg).
  • 95% of patients remained off all topical IOP-lowering medications.
  • 100% achieved 20/30 or better best-corrected distance visual acuity (BCDVA).
  • No product-related adverse events (AEs) reported.

These findings demonstrate long-term, drop-free IOP control and excellent safety following implantation during routine cataract surgery.

Phase I/II Interim Results: Confirmed Efficacy and Safety

The Phase I/II trial is a multicenter, randomized, double-masked, controlled study evaluating two dose levels of the BIM-IOL System (78 mcg and 39 mcg) compared to a control group receiving a standard monofocal IOL plus twice-daily timolol drops.

At three months post-implantation:

  • Mean IOP reduction: 37% (78 mcg) and 36% (39 mcg)—comparable to control (37%).
  • 98% of patients (78 mcg) and 96% (39 mcg) were free of all topical IOP-lowering medications.
  • Vision improvement: 20/40 or better BCDVA, with mean scores equivalent to ~20/20 vision (85–86 letters).

“The implantation procedure during cataract surgery is straightforward, and the three-month data show both sustained IOP reduction and strong visual outcomes,” said Jeffrey Kammer, M.D., associate professor of ophthalmology at Vanderbilt University Medical Center and Phase I/II trial investigator. “Long-term, sustained drug delivery options like this are exactly what our patients need.”

Safety Comparable to Routine Cataract Surgery

At the three-month mark:

  • AE rates were similar across groups: 35.3% (78 mcg), 39.1% (39 mcg), and 33.3% (control).
  • No serious ocular AEs were observed.

The safety profile supports the use of the BIM-IOL System during standard cataract surgery procedures.

About the BIM-IOL System

The SpyGlass BIM-IOL System integrates novel non-bioerodible drug pads containing bimatoprost, a prostaglandin analog first approved by the U.S. FDA in 2001 for topical use to reduce elevated IOP.

Designed to be implanted during routine cataract surgery, the system continuously delivers therapeutic levels of bimatoprost over multiple years, offering a potential drop-free alternative to conventional glaucoma therapy.

Next Steps: Advancing Toward Phase III

SpyGlass continues long-term patient follow-up in both the FIH and Phase I/II studies. The company plans to engage with the U.S. FDA to advance the program toward Phase III clinical trials, followed by a 505(b)(2) New Drug Application (NDA) submission and potential commercial approval.

About SpyGlass Pharma

SpyGlass Pharma is a late-stage biopharmaceutical company committed to transforming the treatment paradigm for chronic eye diseases through long-acting, sustained drug delivery of approved medicines. The company’s proprietary technology platforms aim to eliminate the adherence burden of daily eye drops while improving long-term disease control and visual outcomes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!